Evidence map›Paper›PMID 40699431›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

A Mass Spectrometry-Based Pipeline for Analyzing RNA Modifications in Cells and Tissues.

Aurore Attina, Jérôme Vialaret, Christophe Hirtz, Alexandre David

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Aurore AttinaIRMB-PPC, INM, CHU Montpellier, INSERM, Université de Montpellier, CNRS, Montpellier, Occitanie, France.ORCID https://orcid.org/0009-0001-5261-7438
Jérôme VialaretIRMB-PPC, INM, CHU Montpellier, INSERM, Université de Montpellier, CNRS, Montpellier, Occitanie, France.ORCID https://orcid.org/0000-0002-3730-2366
Christophe HirtzIRMB-PPC, INM, CHU Montpellier, INSERM, Université de Montpellier, CNRS, Montpellier, Occitanie, France.ORCID https://orcid.org/0000-0002-7313-0629
Alexandre DavidIRMB-PPC, INM, CHU Montpellier, INSERM, Université de Montpellier, CNRS, Montpellier, Occitanie, France. alexandre.david@inserm.fr.ORCID https://orcid.org/0000-0003-3365-1339

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mass spectrometry has become indispensable in studying post-transcriptional modifications of RNA, a.k.a. epitranscriptomics, which are crucial for regulating RNA metabolism, gene expression, and major biological processes. Over 150 chemical modifications have been identified across all RNA subtypes. Dysregulation of RNA mark deposition can lead to disease development and progression. Therefore, accurately detecting and characterizing these modifications are vital for understanding their functional impact and uncovering potential therapeutic and diagnostic biomarkers. In this chapter, we describe a mass spectrometry-based method for detecting and quantifying nearly 40 different RNA modifications.

Indexed as

Mass SpectrometryRNARNA Processing, Post-TranscriptionalHumansRNABiomarker discoveryMultiple reaction monitoring (MRM)RNA modificationsTargeted epitranscriptomics

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.